Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PINS Study: Vitamin B Combination in Peripheral Sensory Polyneuropathy
NCT05619328Phase 3Completed
- Sponsor
- Procter & Gamble
- Start
- Sep 2022
- Primary completion
- Nov 2023
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of thiamine, pyridoxine and cyanocobalamin in Peripheral Sensory Polyneuropathy (PSPN) (2 arms), sponsored by Procter & Gamble. Primary endpoint: Neuropathy Total Symptom Score-6 at 120 days. Started Sep 2022; status: completed.
02
Drugs
thiaminepyridoxinecyanocobalamin
03
Conditions
Peripheral Sensory Polyneuropathy (PSPN)
Beyond the preview
Go deeper on NCT05619328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05619328.